Cancer Pain Market Outlook
The global cancer pain market size was valued at USD 6.86 Billion in 2022 and is likely reach to USD 10.92 Billion by 2031, expanding at a CAGR of 5.3% during the forecast period, 2023–2031. The unmet needs in the cancer diagnosis and rise in number of cancer incidence are key factors boosting the market growth.
The segregation of cancer pain is puzzled with complications, despite the pointers show certain indications. To take into account of the existing figures, more than half of the patients having cancer are suffering from low to moderate pain.
A key causative factor is the heterogeneity of pain, by the fact that different etiologies may or may not be related to cancer. Global health agencies such as the World Health Organization (WHO) have been actively focusing in revealing cancer pain management guidelines.
Meanwhile, several research have been undertaken to expand the existing medical knowledge about the effective methods and techniques for cancer pain management. Various measuring tools are being used to develop effective frameworks for characterizing and identification of cancer pain and the acceptance of these equipment are growingly rapidly over the years. .
The presence of key global players in the global cancer pain market has played a crucial role in the market growth. Pain reduction solution has been a salient part of cancer treatment as it helps in executing pain management processing by using proper therapies.
Meanwhile, the COVID-19 situation has negatively affected the market as major pharmaceutical players are more focused in the development of coronavirus diagnostic equipment and other methods for the virus testing.
Market Trends, Drivers, Restraints, and Opportunities
- Growing number of the aging population and rising number of different types of cancer such as blood cancer, bone marrow, and breast cancer across the globe are expected to drive the market growth in the coming years.
- Introduction of painkiller medications and various therapy drugs for the cancer treatment are expected to fuel the market growth.
- Rising surgical treatment for cancer and increasing demand for solution to minimize post-surgical pain of patients are key drivers pushing to increase the market revenue.
- Rapid development and rising adopting of more non-opioid medications for cancer treatment is projected to boost the market expansion during the forecast period.
- High cost of treatment of cancer and lack of awareness regarding the treatment method are major challenges, which are expected to hinder the market expansion.
Scope of Cancer Pain Market Report
The report on the global cancer pain market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Cancer Pain Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drugs Class (Opioids [Semi-synthetic and Synthetic Drugs {Hydrocodone, Oxycodone, and Fentanyl Antagonist Drugs}], Non-steroidal Anti-inflammatory Drugs [Aspirin-like Drugs and Paracetamol], and Others), and Treatments (Immunotherapy, Radiotherapy, Chemotherapy, Hormone therapy, Targeted Therapies, inhibitors, Surgery, and Treatment Choice)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
BioDelivery Science International; ProStrakan Group; Teva Pharmaceutical Industries Limited; Daiichi Sankyo Company, Limited; Galena Biopharma, Grunenthal Group; GW Pharmaceuticals; Hospira, Johnson & Johnson; Meda Pharmaceuticals; Orexo; SANOFI-Synthelabo (India) Private Limited; Sorrento Therapeutics; and WEX Pharmaceuticals.
|
Cancer Pain Market Segment Insights
Opioids segment is expected to grow at a rapid pace
Based on drug class, the global cancer pain market is divided into opioids, non-steroidal anti-inflammatory drugs, and others. The opioids segment is further bifurcated into semi-synthetic and synthetic drugs. The synthetic drugs segment is sub-divided into hydrocodone, oxycodone, and fentanyl antagonist drugs.
On the other hand, the non-steroidal anti-inflammatory drugs segment consists of aspirin-like drugs and paracetamol. The opioids segment is expected to grow at a rapid pace in the coming years as they are largely used to relieve pain of cancer patients in the diagnosis and in post-diagnosis effects on patients.
However, the non-steroidal anti-inflammatory drugs segment is anticipated to account for a key share of the market during the forecast period owing to the adoption of physiologists of these drugs in the diagnosis of cancer.
Targeted therapies segment is projected to expand at a considerable CAGR
On the basis of treatments, the market is divided into immunotherapy, radiotherapy, chemotherapy, hormone therapy, targeted therapies, inhibitors, surgery, and treatment choice. The targeted therapies segment is projected to expand at a considerable CAGR during the forecast period owing to recent advances and developments in gene therapy and cellular technology, which helps in the study of tumor cells.
Meanwhile, the immunotherapy segment is anticipated to expand at a significant growth rate during the forecast period due to increase in number of cancer incidences, which is expected to boost the immunotherapy demand.
Cancer Pain Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the global cancer pain market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the projected period due to increase in number of patients of cancer and early adoption of the drugs by patients.
On the other hand, the market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to increase in surge in research, rise in awareness related to different cancers, development, & innovation activities, and disposable income of a large number of the population in the region.
Segments
Drugs Class
- Opioids
- Semi-synthetic
- Synthetic Drugs
- Hydrocodone
- Oxycodone
- Fentanyl Antagonist Drugs
- Non-steroidal Anti-inflammatory Drugs
- Aspirin-like Drugs
- Paracetamol
- Others
Treatments
- Immunotherapy
- Radiotherapy
- Chemotherapy
- Hormone therapy
- Targeted Therapies
- Inhibitors
- Surgery
- Treatment Choice
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the cancer pain market are BioDelivery Science International; ProStrakan Group; Teva Pharmaceutical Industries Limited; Daiichi Sankyo Company, Limited; Galena Biopharma, Grunenthal Group; GW Pharmaceuticals; Hospira, Johnson & Johnson; Meda Pharmaceuticals; Orexo; SANOFI-Synthelabo (India) Private Limited; Sorrento Therapeutics; and WEX Pharmaceuticals.
Request For Customization
Enquiry Before Buying
Speak With Analyst
